Clinical trials remain the standard for introducing new treatments into the medical armamentarium. There is a wealth of information contained in survival curves that are the ultimate outcomes reported in most oncology clinical trials. Survival curves report interesting information about the disease and its response to treatment. Unfortunately, and all too often, the limitations of survival curves are not adequately presented in publications and alternative interpretations for the data are not meticulously delineated by authors. The danger inherent in any publication of survival is that the data are not sufficiently ‘mature’ to support the conclusions that are drawn. This would be of little consequence if medical decisions were not based upon reading the latest publication that is acclaimed to be definitive and settle the question ‘once and for all.’ Better understanding of survival curves and how they shape the future of clinical practice may reduce the dangers of these pitfalls.

Keywords:
Survival curves, Interpretation of clinical trials, Design of clinical trials
1.
Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I Martino S, Lazarus HM, Erban, JK, Sickles C, Glick JH, Philadelphia Bone Marrow Transplant Group: Conventional-dose chemotherapy compared with high dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000;342:1069–1076.
2.
Lotz J-P, Cure H, Janvier M, Morvan F, Asselain B, Guillemot M, Laaden A, Maraninchi D, Gisselbrecht C, Roche H, PEGASE Group: High-dose chemotherapy (HD-CT) with hematopoietic stem cells (sic) transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol PEGASE 04 (abstract). Proc ASCO 1999;18:43a.
3.
Peters W, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L for CALGB, SWOG and NCIC: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 (abstract). Proc ASCO 1999;18:1a.
4.
The Scandinavian Breast Cancer Study Group 9401: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy (abstract). Proc ASCO 1999;18:2a.
5.
Rodenhuis S, Bontenbal M, Beex L, van der Wall E, Richel D, Noojj M, Voest E, Hupperets P, Westermann A, Dalesio O, de Vries E: Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thioTEPA and carboplatin in operable breast cancer with 4 or more axillary lymph nodes (abstract). Proc ASCO 2000;19:74a.
6.
Singer HW: High-dose chemo effective in breast cancer afterall (sic)? Longer follow-up may explain why patients in a Dutch study appear to be doing so well. Hem/Oncol Today 2000;1:8–9.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.